---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-215909"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:51:33.320690+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Eiger BioPharmaceuticals Chapter 11 liquidation plan confirmed; all equity cancelled

## Summary
- Bankruptcy Court entered confirmation order on Sept 5, 2024, for Fifth Amended Joint Plan of Liquidation.
- All 1,480,797 shares of common stock to be cancelled on effective date; no recovery for equity holders.
- Assets sold: Zokinvy to Sentynl, Avexitide to Amylyx, Lonafarnib/Lambda to Eiger InnoTherapeutics.
- As of July 31, 2024, Debtors reported ~$65.6M assets and ~$40M liabilities (unaudited).
- Liquidating Trustee and Plan Administrator to wind down operations and administer trust assets.

## SEC filing metadata
- accession: 0001193125-24-215909
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.03, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/0001193125-24-215909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/d887098d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-215909
- JSON: https://secwatch.observer/filing/0001193125-24-215909.json
- Plain text: https://secwatch.observer/filing/0001193125-24-215909.txt

## Key facts
- Distress & Bankruptcy
  Eiger BioPharmaceuticals, Inc. entered chapter 11 in United States Bankruptcy Court for the Northern District of Texas (petition 2024-04-01).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court for the Northern District of Texas
  - Petition: 2024-04-01
  source text: As previously disclosed, on April 1, 2024, Eiger BioPharmaceuticals, Inc. (the “ Company ”) and its direct subsidiaries (together the “ Debtors ”) filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the Northern District of Texas (the “ Bankruptcy Court ”) under the caption In re Eiger BioPharmaceuticals, Inc., et al , Case No. 24-80040 (the “ Chapter 11 Cases ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/0001193125-24-215909-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.